Steven C. Quay
Net Worth
Last updated:
What is Steven C. Quay net worth?
The estimated net worth of Dr. Steven C. Quay is at least $11,375,951 as of 30 May 2018. He owns shares worth $6 as insider, has earned $41,105 from insider trading and has received compensation worth at least $11,334,840 in Atossa Therapeutics, Inc..
What is the salary of Steven C. Quay?
Dr. Steven C. Quay salary is $944,570 per year as Chairman, Chief Executive Officer & Pres in Atossa Therapeutics, Inc..
How old is Steven C. Quay?
Dr. Steven C. Quay is 74 years old, born in 1951.
What stocks does Steven C. Quay currently own?
As insider, Dr. Steven C. Quay owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | Chairman, Chief Executive Officer & Pres | 8 | $0.76 | $6 |
What does Atossa Therapeutics, Inc. do?
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Steven C. Quay insider trading
Atossa Therapeutics, Inc.
Dr. Steven C. Quay has made only one insider trade between 2013-2018, according to the Form 4 filled with the SEC. He purchased 8 units of ATOS stock worth $28 on 30 May 2018.
As of 30 May 2018 he still owns at least 8 units of ATOS stock.
Atossa Therapeutics key executives
Atossa Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Steven C. Quay (74) Chairman, Chief Executive Officer & Pres
- Mr. Kyle Guse CPA, Esq., CPA (61) Chief Financial Officer, Gen. Counsel & Sec.